ClinicalTrials.gg
Active, not recruitingNCT06894212Updated Oct 5, 2026

A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia

A Phase 3 interventional study of SEP-363856 and Placebo in Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Active, not recruiting at 73 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Updated Oct 5, 2026Now Active, not recruitingEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
538
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 23 studies testing SEP-363856 in Schizophrenia — 1 open to participants now, 2 under way, 2 of them phase 3. SEP-363856 · Schizophrenia.

Enrollment
Largest of 23
538 · median 83
Started
2025
with 1 other
Phase 3
9 of 23
1 open now
Registered
22nd of 23
by date
Lead sponsor
18 of 23
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 23 studies testing SEP-363856 in Schizophrenia, this one has the largest enrollment, is one of 2 that started in 2025, is one of 9 in phase 3, and was the 22nd registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

1 of the 23 studies testing SEP-363856 in Schizophrenia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About SEP-363856

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing SEP-363856 in Schizophrenia, or all of them as a file.
02

Study summary

Evaluate the efficacy and safety of Ulotaront (SEP-363856) in acutely psychotic subjects with schizophrenia

Read the detailed description

A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants with Schizophrenia

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Male or female participants between 18 to 65 years of age (inclusive) at the time of consent.
  • Participant has an identified reliable informant (eg, caregiver, relative, friend, case worker, residential treatment staff).
  • Participant is experiencing an acute exacerbation or relapse of symptoms, with onset ≤ 2 months prior to screening

    1. The participant requires hospitalization for this acute exacerbation or relapse of symptoms.
    2. If already an inpatient at screening, has been hospitalized for less than 2 weeks for the current exacerbation at the time of screening.
  • Participants who are experiencing an acute exacerbation of psychotic symptoms and marked deterioration of usual function as demonstrated by meeting ALL of the following criteria at the screening and baseline visits:

    1. Participant must have a PANSS total score ≥ 80

      AND

    2. Participant must have a CGI-S score ≥ 4.
  • Participants who have received previous outpatient antipsychotic treatment at an adequate dose (minimal recommended dose for the treatment of schizophrenia according to the manufacturer labeling) for an adequate duration (at least 6 weeks) and who showed a previous good response.

Key Exclusion Criteria:

  • Sexually active participants or persons of who do not agree to practice 2 different clinical trial sponsor approved methods of or remain abstinent during the course of the trial and for 30 days after the last dose of study drug.
  • Participant has a current diagnosis or presence of symptoms consistent with a DSM-5 diagnosis other than schizophrenia.
  • Participant has had psychiatric hospitalization(s) for more than 30 days (cumulative) during the 90 days prior to screening.
  • Participant has previously received SEP-363856 or was previously enrolled in a SEP-363856 clinical study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
538 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo

    Other: Placebo

  • Experimental
    SEP-363856 75 mg

    SEP-363856 75 mg/day

    Drug: SEP-363856

  • Experimental
    SEP-363856 100 mg

    SEP-363856 100 mg/day

    Drug: SEP-363856

Interventions

06

What researchers measure

Primary outcomes

  1. The change from baseline in Positive And Negative Syndrome Scale (PANSS) total score at Week 6

    To evaluate the efficacy of SEP-363856 (75 and 100 mg/day) compared with placebo in acutely psychotic participants with schizophrenia. PANSS total - 30-210 Higher score is indicative of greater symptomatology

    Time frame: Baseline to Week 6

Secondary outcomes

  1. Clinical Global Impression-Severity (CGI-S)

    Change from baseline in CGI-S score at Week 6. CGI-S is 0-7 with higher score is indicative of greater symptomatology

    Time frame: Baseline to Week 6

07

Study locations

73 sites
  • Pillar Clinical Research LLC - Bentonville Site
    Bentonville, Arkansas 72712, United States
  • Pillar Clinical Research (Little Rock AR) Site
    Little Rock, Arkansas 72204, United States
  • Woodland International Research Group Site
    Little Rock, Arkansas 72211, United States
  • Woodland Research Northwest Site
    Rogers, Arkansas 72758, United States
  • Clinical Innovations, Inc. dba CITrials (Bellflower)
    Bellflower, California 90706, United States
  • ProScience Research Group Site
    Culver City, California 90230, United States
  • CenExel CNS - Garden Grove (Collaborative Neuroscience Research) Site
    Garden Grove, California 92845, United States
  • Synergy San Diego Site
    Lemon Grove, California 91945, United States
  • Catalina Research Institute Site
    Montclair, California 91763, United States
  • Clinical Innovations Inc. DBA CITrials (Riverside)
    Riverside, California 92506, United States
  • Richmond Behavioral Associates LLC
    Riverside, California 92506, United States
  • CNRI - San Diego LLC Site
    San Diego, California 92123, United States
  • Schuster Medical Research Institute
    Sherman Oaks, California 91403, United States
  • CenExel CNS - Los Alamitos (Collaborative Neuroscience Research)
    Torrance, California 90504, United States
  • Galiz Research Site
    Hialeah, Florida 33016, United States
  • Segal Trials - Larkin Behavioral Health - Inpatient & Early Phase Site
    Hollywood, Florida 33021, United States
  • Cenexel RCA (Research Centers of America) Site
    Hollywood, Florida 33024, United States
  • Premier Clinical Research Institute
    Miami, Florida 33122, United States
  • D & H National Research Centers NC
    Miami, Florida 33155, United States
  • Innovative Clinical Research, Inc. Site
    Miami Lakes, Florida 33016, United States
  • Health Synergy Clinical Research LLC Site
    West Palm Beach, Florida 33407, United States
  • Synexus Clinical Research US Inc - Atlanta
    Atlanta, Georgia 30328, United States
  • CenExel ACMR (Atlanta Center for Medical Research, LLC) Site
    Atlanta, Georgia 30331, United States
  • CenExel IRA (CenExcel iResearch, LLC) Site
    Decatur, Georgia 30030, United States
  • Accelerated Clinical Trials in Peachtree Corners GA Site
    Peachtree Corners, Georgia 30071, United States
  • Uptown Research Institute
    Chicago, Illinois 60640, United States
  • Pillar Clinical Research LLC (Chicago)
    Chicago, Illinois 60641, United States
  • Eastern Clinical Research Associates
    New Orleans, Louisiana 70127, United States
  • Cenexel CBH (CBH Health)
    Gaithersburg, Maryland 20877, United States
  • Hassman Research Institute, LLC
    Marlton, New Jersey 20877, United States
  • Neuro-Behavioral Clinical Research Site
    North Canton, Ohio 44720, United States
  • Community Clinical Research Inc
    Austin, Texas 78754, United States
  • InSite Clinical Research
    DeSoto, Texas 75115, United States
  • HD Research - Memorial Hermann Surgery Center Memorial Village
    Houston, Texas 77043, United States
  • Pillar Clinical Research LLC (Richardson, TX) Site
    Richardson, Texas 75080, United States
  • Hotei Hospital
    Konan-shi, Aichi-ken 483-8248, Japan
  • Seishinkai Okehazama Hospital
    Toyoake-shi, Aichi-ken 470-1168, Japan
  • Seijinkai Seinan Hospital
    Hachinohe-shi, Aomori 039-1104, Japan
  • National Hospital Organization Shimofusa Psychiatric Medical Center
    Chiba, Chiba 266-0007, Japan
  • National Kohnodai Medical Center
    Ichikawa-shi, Chiba 272-8516, Japan
  • Fukuoka University Hospital
    Fukuoka, Fukuoka 814-0180, Japan
  • Kuramitsu Hospital
    Fukuoka, Fukuoka 819-0037, Japan
  • National Hospital Organization Kokura Medical Center Site
    Kokuraminami-ku, Kitakyushu-shi, Fukuoka 802-8533, Japan
  • Shiranui Hospital
    Omuta-shi, Fukuoka 836-0004, Japan
  • Social Medical Corporation Asaka Hospital
    Kōriyama, Fukushima 963-0198, Japan
  • Hayakawa Clinic
    Kure, Hiroshima 737-0111, Japan
  • NHO Kure Medical Center
    Kure-shi, Hiroshima 737-0023, Japan
  • Nayoro City General Hospital
    Nayoro-shi, Hokkaido 096-8511, Japan
  • Obihiro Kosei Hospital
    Obihiro, Hokkaido 080-0024, Japan
  • Goryokai Medical Corporation Hospital
    Sapporo, Hokkaido 002-8029, Japan
  • Iwate Medical University Hospital
    Shiwa-gun, Iwate 028-3695, Japan
  • Hatano Kousei Hospital
    Hadano-shi, Kanagawa 257-0003, Japan
  • Tanzawa Hospital
    Hadano-shi, Kanagawa 259-1304, Japan
  • Fujimidai Hospital Site
    Hiratsuka-shi, Kanagawa 259-1205, Japan
  • Yokohama Hino Hospital
    Yokohama, Kanagawa 234-0051, Japan
  • Yuge Hospital
    Kumamoto, Kumamoto 861-8002, Japan
  • Miyakonojo Shinsei Hospital
    Miyakonojo-shi, Miyazaki 885-0093, Japan
  • Kansai Medical University Medical Center
    Moriguchi-shi, Osaka 570-8507, Japan
  • Neyagawa Sanatorium
    Neyagawa, Osaka 572-0854, Japan
  • National Hospital Organization Hizen Psychiatric Medical Center Site
    Kanzaki-gun, Saga-ken 842-0192, Japan
  • Rainbow and Sea Hospital
    Karatsu-shi, Saga-ken 847-0031, Japan
  • Inuo Hospital
    Tosu-shi, Saga-ken 841-0081, Japan
  • Shiga University of Medical Science Hospital
    Ōtsu, Shiga 520-2192, Japan
  • Dokkyo Medical University Hospital
    Shimotsuga-gun, Tochigi 321-0293, Japan
  • Jichi Medical University Hospital
    Shimotsuke-Shi, Tochigi 329-0498, Japan
  • Tochigi Prefectural Okamotodai Hospital
    Utsunomiya, Tochigi 329-1104, Japan
  • National Center of Neurology and Psychiatry
    Kodaira-shi, Tokyo 187-8551, Japan
  • Asuka Hospital
    Machida-shi, Tokyo 194-0005, Japan
  • Showa Medical University Karasuyama Hospital
    Setagaya-ku, Tokyo 157-8577, Japan
  • Toyama Prefectural Center Hospital
    Toyama, Toyama 930-8550, Japan
  • Sanyo Hospital
    Sakata-shi, Yamagata 998-0074, Japan
  • Yamagata Sakuracho Hospital Site
    Yamagata, Yamagata 990-0045, Japan
  • Wakayama Medical University Hospital
    Wakayama, 641-8510, Japan
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the result of this study will be shared with researchers to achieve aims pre-specified in a methodology sound research proposal. Small studies with less than 25 participants are excluded from data sharing.

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: http://vivli.org/ourmember/Otsuka/

Data sharing details ↗ · clinical-trials.otsuka.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Oct 2026, 19 months after the start.

Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's planned 19 months is below that.

Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2025
First posted
Mar 25, 2025
StartActual
Feb 28, 2025
Primary completionEst.
Oct 20, 2026
CompletionEst.
Oct 29, 2026
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 5, 2026
Enrollment
522 (estimated)→538 (actual)
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Recruiting→Active, not recruiting
    Enrollment 522 (estimated)→538 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06894212
Responsible party
Sponsor
First posted
Mar 25, 2025
Start date
Feb 28, 2025
Primary completion
Oct 20, 2026 (estimated)
Completion
Oct 29, 2026 (estimated)
Last update
Oct 5, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SEP-363856

Start the discussion